These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33458807)

  • 1. Use of bisphosphonates in multiple myeloma patients in Denmark, 2005-2015.
    Olesen TB; Andersen IT; Ording AG; Ehrenstein V; Seesaghur A; Helleberg C; Silkjær T; Hernandez RK; Niepel D; Abildgaard N
    Support Care Cancer; 2021 Aug; 29(8):4501-4511. PubMed ID: 33458807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
    Morgan GJ; Davies FE; Gregory WM; Cocks K; Bell SE; Szubert AJ; Navarro-Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross F; Byrne J; Roddie H; Rudin C; Cook G; Jackson GH; Child JA;
    Lancet; 2010 Dec; 376(9757):1989-99. PubMed ID: 21131037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone complications in patients with multiple myeloma in five European countries: a retrospective patient chart review.
    Mateos MV; Fink L; Koneswaran N; Intorcia M; Giannopoulou C; Niepel D; Cavo M
    BMC Cancer; 2020 Mar; 20(1):170. PubMed ID: 32126974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Practice guidelines of the use of bisphosphonates in solid tumours with bone metastases and in multiple myeloma].
    Brantus JF; Roemer-Becuwe C; Cony-Makhoul P; Salino S; Fontana A; Debourdeau P; Thomas T; Guastalla JP; Ghesquieres H; Sebban C; Pavic M; Collet P; Larbre JP; Martinon S; Brocard F; Bodard AG; Blanc G; Balestrière V; Favier B; Farsi F; Krakowski I; Biron P;
    Rev Med Interne; 2011 Aug; 32(8):494-505. PubMed ID: 21376431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of bisphosphonate treatment among patients with multiple myeloma treated at oncology clinics across the USA: observations from real-world data.
    Kim C; Hernandez RK; Cyprien L; Liede A; Cheng PC
    Support Care Cancer; 2018 Aug; 26(8):2833-2841. PubMed ID: 29516168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates in multiple myeloma: a network meta-analysis.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates for Patients Diagnosed With Multiple Myeloma.
    Mhaskar R; Djulbegovic B
    JAMA; 2018 Oct; 320(14):1483-1484. PubMed ID: 30326511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates for breast cancer.
    Pavlakis N; Schmidt R; Stockler M
    Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonate anticancer activity in multiple myeloma.
    Terpos E
    Anticancer Agents Med Chem; 2012 Feb; 12(2):123-8. PubMed ID: 21864228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial.
    Morgan GJ; Child JA; Gregory WM; Szubert AJ; Cocks K; Bell SE; Navarro-Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross FM; Byrne J; Roddie H; Rudin C; Cook G; Jackson GH; Wu P; Davies FE;
    Lancet Oncol; 2011 Aug; 12(8):743-52. PubMed ID: 21771568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
    Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
    J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates--role in cancer therapies.
    Mehrotra B
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):19-26. PubMed ID: 19371811
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of bisphosphonates in orthopedic surgery: pearls and pitfalls.
    Lozano-Calderon SA; Colman MW; Raskin KA; Hornicek FJ; Gebhardt M
    Orthop Clin North Am; 2014 Jul; 45(3):403-16. PubMed ID: 24975766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates in multiple myeloma.
    Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
    Cochrane Database Syst Rev; 2010 Mar; (3):CD003188. PubMed ID: 20238320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonate therapy in the treatment of multiple myeloma.
    Lawson MA; Ashcroft J; Croucher PI
    Curr Pharm Des; 2010; 16(27):3028-36. PubMed ID: 20722619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.
    Jackson GH; Morgan GJ; Davies FE; Wu P; Gregory WM; Bell SE; Szubert AJ; Navarro Coy N; Drayson MT; Owen RG; Feyler S; Ashcroft AJ; Ross FM; Byrne J; Roddie H; Rudin C; Boyd KD; Osborne WL; Cook G; Child JA
    Br J Haematol; 2014 Jul; 166(1):109-17. PubMed ID: 24673708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.
    Morgan GJ; Davies FE; Gregory WM; Szubert AJ; Bell SE; Drayson MT; Owen RG; Ashcroft AJ; Jackson GH; Child JA;
    Blood; 2012 Jun; 119(23):5374-83. PubMed ID: 22498739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma.
    Sanfilippo KM; Gage B; Luo S; Weilbaecher K; Tomasson M; Vij R; Colditz G; Carson K
    Leuk Lymphoma; 2015 Mar; 56(3):615-21. PubMed ID: 24844358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: paradoxical complication of treatment of bone lesions in multiple myeloma patients.
    Capalbo S; Delia M; Diomede D; Dargenio M; Chiefa A; Favia G; Liso V
    Int J Hematol; 2006 Jun; 83(5):439-42. PubMed ID: 16787865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Jaw avascular osteonecrosis after treatment of multiple myeloma with zoledronate.
    Lobato JV; Maurício AC; Rodrigues JM; Cavaleiro MV; Cortez PP; Xavier L; Botelho C; Hussain NS; Santos JD
    J Plast Reconstr Aesthet Surg; 2008; 61(1):99-106. PubMed ID: 18068658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.